` CMRX (Chimerix Inc) vs S&P 500 Comparison - Alpha Spread

CMRX
vs
S&P 500

Over the past 12 months, CMRX has significantly outperformed S&P 500, delivering a return of +844% compared to the S&P 500's +13% growth.

Stocks Performance
CMRX vs S&P 500

Loading
CMRX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CMRX vs S&P 500

Loading
CMRX
S&P 500
Difference
www.alphaspread.com

Performance By Year
CMRX vs S&P 500

Loading
CMRX
S&P 500
Add Stock

Competitors Performance
Chimerix Inc vs Peers

S&P 500
CMRX
ABBV
AMGN
GILD
VRTX
Add Stock

Chimerix Inc
Glance View

Market Cap
787.5m USD
Industry
Biotechnology

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 87 full-time employees. The company went IPO on 2013-04-11. The firm is focused on discovering, developing and commercializing medicines that address unmet medical needs. The firm offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The firm's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.

CMRX Intrinsic Value
4.99 USD
Overvaluation 42%
Intrinsic Value
Price
Back to Top